{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"307"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"}],"units":"Participants"}],"description":"The NINLARO additional risk minimization measure (aRMM) effectiveness study questionnaire which was intended for pharmacists who instructed the dosing of IRD therapy to patients with relapsed/refractory multiple myeloma (RRMM). This outcome was based on the number of pharmacists who answered \"Yes\" to question 3; Do you instruct patients that they should take one capsule of NINLARO each time on an empty stomach for RRMM? Here, unit of measure: participants refer to pharmacists.","groups":[{"description":"Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.","id":"OG000","title":"Pharmacists in Hospitals Prescribing NINLARO"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The final analysis set included all pharmacists who consented to participate in the survey, passed the screening questions, and completed all questions.","reportingStatus":"POSTED","timeFrame":"Up to Day 9","title":"Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material","type":"PRIMARY","unitOfMeasure":"Participants"}